Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03282344 · ClinicalTrials.gov registry record · Phase 2

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

A Phase 2 study of Sarcoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
88
Enrollment target
2
Study locations

NCT03282344 is a Phase 2 study of Sarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 88 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03282344, a Phase 2 study of Sarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
88 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to test any good and bad effects of the combination of study drugs called NKTR-214 and nivolumab.

Conditions Studied

Sarcoma

Interventions

  • DRUG Nivolumab
  • DRUG NKTR-214

Study Locations (2)

New York

  • Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort) - New York

Texas

  • MD Anderson Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort) - Houston

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2017-09-12
Est. Completion 2026-09
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03282344

The ClinicalTrials.gov registry entry for NCT03282344 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (90% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT03282344 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Texas.

Frequently Asked Questions

What is clinical trial NCT03282344 about?

NCT03282344 is a clinical study titled "A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma". The purpose of this study is to test any good and bad effects of the combination of study drugs called NKTR-214 and nivolumab.

What is the current status of trial NCT03282344?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2017-09-12. Estimated completion is 2026-09.

What conditions does trial NCT03282344 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT03282344?

The interventions under investigation include: Nivolumab (DRUG), NKTR-214 (DRUG).

Who is sponsoring clinical trial NCT03282344?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03282344 being conducted?

This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.